replicateBE: Average Bioequivalence with Expanding Limits (ABEL)

Performs comparative bioavailability calculations for Average Bioequivalence with Expanding Limits (ABEL). Implemented are 'Method A' / 'Method B' and the detection of outliers. If the design allows, assessment of the empiric Type I Error and iteratively adjusting alpha to control the consumer risk. Average Bioequivalence - optionally with a tighter (narrow therapeutic index drugs) or wider acceptance range (South Africa: Cmax) - is implemented as well.

Version: 1.1.3
Depends: R (≥ 3.5.0)
Imports: readxl (≥ 1.0.0), PowerTOST (≥ 1.5.3), lmerTest, nlme, pbkrtest, graphics, grDevices
Suggests: knitr, rmarkdown, testthat, devtools
Published: 2022-05-02
DOI: 10.32614/CRAN.package.replicateBE
Author: Helmut Schütz ORCID iD [aut, cre], Michael Tomashevskiy [ctb], Detlew Labes ORCID iD [ctb]
Maintainer: Helmut Schütz <helmut.schuetz at>
License: GPL (≥ 3)
NeedsCompilation: no
Materials: README NEWS
In views: ClinicalTrials
CRAN checks: replicateBE results


Reference manual: replicateBE.pdf
Vignettes: replicateBE


Package source: replicateBE_1.1.3.tar.gz
Windows binaries: r-devel:, r-release:, r-oldrel:
macOS binaries: r-release (arm64): replicateBE_1.1.3.tgz, r-oldrel (arm64): replicateBE_1.1.3.tgz, r-release (x86_64): replicateBE_1.1.3.tgz, r-oldrel (x86_64): replicateBE_1.1.3.tgz
Old sources: replicateBE archive


Please use the canonical form to link to this page.